MARKET

TCON

TCON

TRACON Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.00
+0.13
+1.65%
After Hours: 8.10 +0.1 +1.25% 18:55 04/13 EDT
OPEN
7.83
PREV CLOSE
7.87
HIGH
8.04
LOW
7.59
VOLUME
191.20K
TURNOVER
--
52 WEEK HIGH
12.20
52 WEEK LOW
1.550
MARKET CAP
123.83M
P/E (TTM)
-3.6934
1D
5D
1M
3M
1Y
5Y
Renal Cell Cacinoma Drugs Market Aims to Expand at Double-Digit Growth Rate By 2027
Apr 06, 2021 (Market Stats News via COMTEX) -- A new market research report titled "Global Renal Cell Cacinoma Drugs Market 2021 Analysis and Industry...
Market Stats News · 04/06 21:21
DJ Tracon Pharmaceuticals Initiated at Buy by Jones Trading
Dow Jones · 04/01 15:10
DJ Tracon Pharmaceuticals Price Target Announced at $17.00/Share by Jones Trading
Dow Jones · 04/01 15:10
Renal Cell Cacinoma Drugs Market Research Growth Manufacturers, Regions, Type and Application, Forecast Analysis to 2020-2027 By Ameco Research
pune, India, Thu, 25 Mar 2021 03:31:29 / Comserve Inc. / -- The global Renal Cell Cacinoma Drugs market is segmented by company, region (country), by Type,...
Comserve · 03/25 07:33
TRACON Pharmaceuticals Announces Poster Presentation at the 2021 AACR Virtual Annual Meeting
Poster to Highlight ENVASARC Pivotal Trial Evaluating Envafolimab in SarcomaSAN DIEGO, March 23, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of ...
GlobeNewswire · 03/23 13:05
8-K: Tracon Pharmaceuticals, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/15 20:40
Global Myocardial Fibrosis Market 2020 Regional Markets, Subcomponent Manufacturers, Business Standards and Forecast to 2025
CDN Newswire · 03/10 19:03
TRACON Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference
SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-indep...
GlobeNewswire · 03/09 13:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TCON. Analyze the recent business situations of TRACON Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TCON stock price target is 15.20 with a high estimate of 24.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 8.86M
% Owned: 57.23%
Shares Outstanding: 15.48M
TypeInstitutionsShares
Increased
12
1.93M
New
15
996.28K
Decreased
4
110.51K
Sold Out
3
75.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
President/Chief Executive Officer/Director
Charles Theuer
Chief Financial Officer/Chief Accounting Officer
Scott Brown
Other
H Logan
Executive Vice President
Bonne Adams
Executive Vice President
Suzy Benedict
Other
Mark Wiggins
Director
Lisa Johnson-Pratt
Director
Saundra Pelletier
Independent Director
William LaRue
Independent Director
Martin Mattingly
Independent Director
J. Rainer Twiford
Independent Director
Stephen Worland
No Data
About TCON
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Webull offers kinds of TRACON Pharmaceuticals Inc stock information, including NASDAQ:TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCON stock methods without spending real money on the virtual paper trading platform.